Fibrotic burden during antiviral therapy for chronic hepatitis B, not <scp>ALT</scp> level, independently predicts liver cancer risk-Reference-Cited by-同舟云学术

Fibrotic burden during antiviral therapy for chronic hepatitis B, not ALT level, independently predicts liver cancer risk

Published:2022-05-10 Issue:8 Volume:42 Page:1902-1906
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver International

Author:

Kim David Sooik¹,Kim Beom Kyung²^ORCID,Seo Yeon Seok³^ORCID,Kim Byung Seok⁴,Jang Byoung Kuk⁵,Kim Sang Gyune⁶^ORCID,Suk Ki Tae⁷,Lee Jin‐Woo⁸,Jeong Soung Won⁹,Kim Seung Up²^ORCID,

Affiliation:

1. Yonsei University College of Medicine Seoul Republic of Korea

2. Department of Internal Medicine Yonsei University College of Medicine Seoul Republic of Korea

3. Department of Internal Medicine Korea University College of Medicine Seoul Republic of Korea

4. Department of Internal Medicine Catholic University of Daegu School of Medicine Daegu Republic of Korea

5. Department of Internal Medicine Keimyung University School of Medicine Daegu Republic of Korea

6. Department of Internal Medicine Soonchunhyang University College of Medicine Bucheon Hospital Bucheon Republic of Korea

7. Department of Internal Medicine Hallym University College of Medicine Chuncheon Republic of Korea

8. Department of Internal Medicine Inha University School of Medicine Incheon Republic of Korea

9. Department of Internal Medicine Soonchunhyang University College of Medicine Seoul Hospital Seoul Republic of Korea

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.15282

Reference10 articles.

1. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop

2. Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status

3. Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B

4. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

5. Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis;Clinical Gastroenterology and Hepatology;2022-11